Form 4: LeMaitre Vascular CFO Reports Dividend Equivalent Rights
Statement of Changes in Beneficial Ownership
CFO Dorian Paul LeBlanc acquired additional dividend equivalent rights related to existing restricted stock unit awards.
Summary
- Dorian Paul LeBlanc, Chief Financial Officer of LeMaitre Vascular, Inc., reported the acquisition of dividend equivalent rights.
- A total of 2.4759 rights were acquired on 06/04/2026 related to a 03/10/2025 RSU award.
- A total of 3.1523 rights were acquired on 06/04/2026 related to a 12/10/2025 RSU award.
- These rights are the economic equivalent of one share of common stock and vest proportionately with the underlying awards.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral, routine disclosure of executive compensation adjustments.
Positives
- Reflects ongoing accumulation of equity-linked compensation by the CFO, aligning interests with shareholders.
Negatives
- None.
Risks
- Value of these rights is dependent on the future performance of LeMaitre Vascular common stock.
Future Outlook
The rights will vest proportionately with the underlying restricted stock unit awards granted in 2025.
Industry Context
StockSavvy.ai notes that this is a routine administrative filing regarding executive compensation and does not signal a change in corporate strategy or market outlook.
Comparison to Industry Standards
- Standard practice for medical device companies to issue dividend equivalent rights to executives as part of long-term incentive plans.
Stakeholder Impact
- Minimal impact on shareholders as this represents standard executive compensation accrual.
Next Steps
- Vesting of the underlying restricted stock units according to the original grant schedules.
Key Dates
| Date | Description |
|---|---|
| 03/10/2025 | Grant date of original RSU award for first set of rights. |
| 12/10/2025 | Grant date of original RSU award for second set of rights. |
| 06/04/2026 | Transaction date for the acquisition of dividend equivalent rights. |
| 06/05/2026 | Filing date of the Form 4. |
Keywords
LeMaitre Vascular, LMAT, Form 4, Insider Trading, Dividend Equivalent Rights, CFO
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.